







Table 1. Summary of adverse events in patients receiving Clozaril (n = 10,000)

Table 2. Summary of adverse events in patients receiving Clozaril (n = 10,000)

|         | Total | Group 1       | Group 2   | Group 3     | Group 4    | Group 5   | Group 6    | Group 7       | Group 8   |
|---------|-------|---------------|-----------|-------------|------------|-----------|------------|---------------|-----------|
| Group 1 | 1,600 | 785 (49.1%)   | 30 (1.9%) | 169 (10.6%) | 87 (5.4%)  | 2 (0.1%)  | 95 (5.9%)  | 372 (23.2%)   | 60 (3.8%) |
| Group 2 | 4,261 | 1,974 (46.3%) | 43 (1.0%) | 413 (9.7%)  | 214 (5.0%) | 7 (0.1%)  | 199 (4.7%) | 1,386 (32.5%) | 25 (0.6%) |
| Group 3 | 2,490 | 945 (38.0%)   | 45 (1.8%) | 298 (12.0%) | 198 (8.0%) | 2 (<0.1%) | 100 (4.0%) | 848 (34.1%)   | 54 (2.2%) |

a) Group 1: Clozaril 12.5 mg b) Group 2: Clozaril 25 mg

Table 3. Summary of adverse events in patients receiving Clozaril (n = 10,000)

Table 4. Summary of adverse events in patients receiving Clozaril (n = 10,000)

Table 5. Summary of adverse events in patients receiving Clozaril (n = 10,000)

<mailto:clozaril.remote@novartis.com>

1-800-222-8814

9:00 AM - 5:30 PM

Table 6. Summary of adverse events in patients receiving Clozaril (n = 10,000)

1-800-0120-003-293

9:00 AM - 5:30 PM

Table 7. Summary of adverse events in patients receiving Clozaril (n = 10,000)

Source URL: <https://www.pro.novartis.com/jp-ja/products/clozaril/clinical/10>